Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses

Nikolaos Pyrgidis 1,2, Ioannis Mykoniatis 1,2, Anna-Bettina Haidich 3, Maria Tirta,2 Persefoni Talimtzi,3 Dimitrios Kalyvianakis,1,2 Andreas Ouranidis,4 Dimitrios Hatzichristou1,2

ABSTRACT

Introduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination therapy in non-responders to PDE5i. We will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.

Methods and analysis This overview was designed in accordance with the PRISMA-framework and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and its protocol was registered at PROSPERO. We will systematically search PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. We will include systematic reviews or meta-analyses: (1) comparing the efficacy and safety of any dose of PDE5i with each other, with placebo or with other effective treatments for the management of erectile function; (2) exploring the use of any PDE5i alone or in combination with other treatment modalities in the general male population or in specific subgroups and (3) conducted with systematic procedures. Our overview will employ the AMSTAR 2 tool to evaluate the quality of the included studies and the Grading of Recommendations Assessment, Development and Evaluation approach to assess the strength of evidence for all outcomes. We will construct forest plots of risk estimates with the corresponding CI for all outcomes.

Ethics and dissemination In this overview, we will undertake an extensive literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i versus another or versus placebo and provide recommendations for clinicians and policy-makers. No ethical approval is required.

PROSPERO registration number CRD42020216754.

INTRODUCTION

Sildenafil was initially developed for the treatment of angina pectoris but its effect on erectile function has brought on a revolution in the management of erectile dysfunction (ED).1 Thereafter, other phosphodiesterase-type 5 inhibitors (PDE5i) have demonstrated their efficacy and safety for the treatment of ED.2 Seven PDE5i (avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, udenafil and vardenafl) at different dosages and formulations are currently available and four of them (avanafil, sildenafil, tadalafil and vardenafil) are considered the first-line option for ED.3 Accumulating evidence suggests that PDE5i may also be safe and effective in many patient groups such as in individuals with diabetes, hypertension, benign prostatic hyperplasia, prostatectomy-induced ED or end-stage renal disease.4 5 Similarly, previous systematic reviews and meta-analyses indicate that PDE5i may be used in combination with other effective treatment modalities such as intracavernosal injections or low-intensity extracorporeal shockwave therapy in non-responders to PDE5i.6

Strengths and limitations of this study

► We will provide the first overview exploring the use of phosphodiesterase-type 5 inhibitors (PDE5i) for the treatment of erectile dysfunction.
► We will assess, in a holistic approach, the safety and efficacy of PDE5i.
► We will evaluate the quality and the strength of evidence deriving from systematic reviews, meta-analyses and network meta-analyses in an attempt to affect clinical and policy decisions.
► Due to the excess of available primary studies, we will not search for recently published randomised controlled trials.
► We will not extract data from the primary studies but rely on the information provided by the relevant systematic reviews and meta-analyses.
Clinicians and policy-makers require a comprehensive overview of the available evidence in order to determine the potential benefits and harms of PDE5i. Within this framework, overviews of systematic reviews and meta-analyses are a relatively new approach that provides a holistic approach of a given topic and aids evidence-based clinical decision making. They aim to summarise and evaluate the strength of scientific evidence as presented in multiple systematic reviews, meta-analyses or network meta-analyses. These studies are becoming increasingly more common in many healthcare domains and in sexual medicine as they provide higher level of recommendations and highlight the gaps in the literature.

Aim
In this context, we will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.

METHODS AND ANALYSIS
This overview of systematic reviews was designed in accordance with the Preferred Reporting Items for Overviews of systematic reviews PRIO-harms guidelines. Our protocol was drafted based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Protocols (online data supplemental file 1).

Search strategy
Two independent reviewers will conduct a systematic literature search of PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. The search terms will include: (systematic review OR meta-analysis) AND (phosphodiesterase-5 OR sildenafil OR tadalafil OR avanafil OR vardenafil OR mirodenafil OR udenafil OR lodenafil) AND (erectile OR erection OR orgasm OR impotence OR IIEF) as well as relevant synonyms, truncated words and MeSH terms. The search strategy developed for PubMed is depicted in online data supplemental file 2. To identify additional articles meeting our inclusion criteria, we will handsearch the reference lists of all eligible studies and sources of grey literature, such as conference abstracts published in major urology and sexual medicine journals. If we identify a study in a language not spoken from the study authors, it will be translated either via a native speaker or a machine translator. We will reupdate all searches before final analyses.

Selection criteria
We will comprise systematic reviews with or without meta-analyses in patients with ED that: (1) provide outcomes deriving from randomised controlled trials; (2) compare the efficacy and safety of any dose of PDE5i with another PDE5i, with placebo or with other effective treatments; (3) explore the use of any approved PDE5i (avanafil, sildenafil, tadalafil, vardenafil) alone or in combination with other treatment modalities both in the general male population as well as in specific subgroups and (4) were conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA statement. On the contrary, we will exclude: (1) systematic reviews or meta-analyses on patients under 18 years of age; (2) systematic reviews or meta-analyses assessing the efficacy and safety of PDE5i for indications not relevant to erectile function and (3) narrative reviews, editorials and letters to the editor.

Outcomes
The primary outcome of our overview will be the improvement of erectile function in the general population. This will be defined as the mean change in the erectile function after PDE5i administration measured with the International Index of Erectile Function (IIEF). Secondary outcomes will include (1) improvement of erectile function based on the IIEF in specific subpopulations such as patients with diabetes, hypertension, end-stage renal disease, adiposity, lower urinary tract symptoms, hypogonadism, radical prostatectomy-induced ED as part of a penile rehabilitation strategy or as an adjunct treatment, depression, psychiatric or neurological disorders, monotherapy-resistant ED as well as elderly and young individuals or other subgroups of patients; (2) severe adverse events after PDE5i intake both in the general population as well as in specific patient subgroups and (3) drop-out rates after treatment with PDE5i. All outcomes will be presented as defined in each included systematic review or meta-analysis.

Study selection and data collection
Two authors will independently search the predetermined electronic databases and the sources of grey literature. After removing duplicate records, the two authors will evaluate the relevance of all retrieved records to the prespecified inclusion criteria, based on title and abstract. Subsequently, the potentially eligible systematic reviews and meta-analyses will be assessed in the full-text form for final inclusion to our overview. All reasons for exclusion will be documented. Any disagreements will be resolved by consensus.

Data extraction will be performed independently by two authors based on a predefined Microsoft Excel spreadsheet. We will tabulate information regarding systematic review or meta-analysis characteristics, interventional details and outcomes. To ensure coherence between the authors, a pilot test will be performed before data extraction.

Quality assessment and strength of evidence
Our overview will employ the A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 tool to evaluate the quality of the included systematic reviews or meta-analyses. The strength of evidence for all outcomes will be based on the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach. If GRADE was applied in an included systematic review, meta-analysis or network meta-analysis, it will be reported as determined from the authors. On the contrary, if GRADE was not performed, we will assess the strength of evidence based on the reported results from this systematic review or meta-analysis. In particular, two reviewers will evaluate risk of bias, inconsistency, indirectness, imprecision and publication bias among trials included in each systematic review or meta-analysis. Any disagreements will be resolved by consensus.

Data synthesis
A descriptive analysis will be performed and the extent of overlapping among systematic reviews and meta-analyses will be estimated applying the corrected covered area and will be presented using novel graphical approaches. When a systematic review and a meta-analysis addressing the same outcome will be identified, data from the meta-analysis will be reported, provided that the meta-analysis includes more primary studies. Similarly, when a systematic review or a meta-analysis and a network meta-analysis addressing the same outcome will be identified, data from the network meta-analysis will be reported, provided that the network meta-analysis includes more primary studies. Among studies with the same design (systematic reviews or meta-analyses or network meta-analyses) assessing similar outcomes, only data from the most recent study will be considered. However, if these meta-analyses were published at a similar period (within 24 months), data from the most methodologically rigorous study will be provided (based on AMSTAR 2). Furthermore, in studies reporting outcomes for erectile function change after PDE5i intake both with validated and non-validated or dichotomous (yes/no) questionnaires, data concerning the validated questionnaire will only be retrieved.

We will construct forest plots of risk estimates with the corresponding CI for all outcomes. In particular, meta-analytical effects for common themes as reported in each study (such as risk ratio, OR or mean difference) will be pooled to provide a descriptive estimate. Additionally, we will evaluate heterogeneity with the I2 and estimation of publication bias with the Egger’s test for each outcome. Meta-analyses performed with a fixed effects model will be reanalysed using the DerSimonian and Laird random effects model. Outcome data will be extracted as reported in each meta-analysis without reviewing the relevant primary studies. All analyses will be performed using Microsoft Excel (V.16.42) and R statistical software (V.3.6.3).

Patients and public involvement
This overview of systematic reviews was conceptualised and developed due to the unmet need of male patients and their partners to receive an effective and safe treatment for ED. Even though our study will not involve patients at any step of its implementation, the results of the overall project will be sent to the communication department of Aristotle University of Thessaloniki for a press release. Moreover, because of the growing interest in this topic, the results of the study will not only be published in scientific journals, but also in more general or multidisciplinary journals to reach a broader audience. Of importance, this study will pinpoint the current gaps in the literature and serve as a valuable guide for the design and implementation of further research on the field, improving healthcare facilities and aiding clinicians to properly consult and treat patients with ED receiving PDE5i.

ETHICS AND DISSEMINATION
Patients and public were not involved for this study protocol and no primary data were collected from individuals. Therefore, no ethics committee approval was required for the present study. In this overview of systematic reviews and meta-analyses, we will undertake an extensive and systematic literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i vs another or placebo. Accordingly, we will assess the effects of PDE5i as part of combination therapy. We will provide relevant recommendations that may serve as a basis for clinicians and policy-makers. Our data will be disseminated through a publication in a prestigious, peer-reviewed journal as well as through conference presentations.

Contributors NP, IM, A-BH, AO and DH contributed to the conception or design of the work. NP, IM, A-BH, MT, PT and DK contributed to the acquisition, analysis or interpretation of data for the work. NP and IM drafted the manuscript. A-BH, MT, PT, DK, AO and DH critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Funding This research will be cofinanced by the European Union and Greek national funds through the Operational Programme Competitiveness, Entrepreneurship and Innovation, under the call RESEARCHCREATEINNOVATE (project code: T1EDK-00540).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Nikolaos Pyrgidis http://orcid.org/0000-0002-7707-8426
Anna-Bettina Haidich http://orcid.org/0000-0001-5100-8799
REFERENCES